FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

مكتبة الأكواد

Nootropic Focus

Cognitive Enhancementintermediate

84

التعاون

84
Share
البروتيدات

2

متوسط الجرعة اليومية (mcg)

1,000

المستوى

intermediate

تمت الإضافة

May 17, 2026

نظرة عامة

The Nootropic Focus stack combines two Russian-developed neuropeptides that operate through complementary mechanisms to enhance cognitive performance while reducing anxiety. Semax is a synthetic analog of ACTH(4-10) — the fragment of adrenocorticotropic hormone responsible for its cognitive effects without the adrenal-stimulating properties. Semax increases brain-derived neurotrophic factor (BDNF) expression by 3-4x in the hippocampus and prefrontal cortex, promotes nerve growth factor (NGF) synthesis, and modulates dopaminergic and serotonergic neurotransmission. In Russian clinical use since 1994, it is prescribed for cognitive impairment, stroke recovery, and optic nerve atrophy. Selank is a synthetic analog of the naturally occurring immunomodulatory peptide tuftsin, with an additional Pro-Gly-Pro sequence that increases its stability and CNS penetration. Selank''s primary mechanism involves modulation of the GABAergic system — it acts as an anxiolytic without the sedation, cognitive impairment, or addiction potential of benzodiazepines. It also influences the expression of BDNF and enkephalins, creating a calm-but-focused mental state rather than the wired alertness of stimulants. The synergy between Semax and Selank is particularly elegant for cognitive enhancement: Semax provides the "drive" component — increased BDNF, enhanced dopaminergic tone, improved attention and working memory — while Selank provides the "calm" component — reduced anxiety, stabilized mood, and prevention of the stress response that impairs prefrontal function. Together they create a state of relaxed concentration ideal for demanding cognitive work. Both are administered nasally for direct access to the CNS via the olfactory epithelium, bypassing the blood-brain barrier. The nasal route provides onset within 5-15 minutes and duration of 4-6 hours.

بروتوكول الجرعة

600 mcg

كل جرعة

400 mcg

كل جرعة

الأهداف والدليل

FocusMemoryAnxiety reductionCognitive enhancementBDNF
درجة الدليل:تجربة عشوائية مزدوجة المراقبة البشرية

تحذيرات

  • Semax and Selank are approved medications in Russia. Not FDA-approved in US. Available as research peptides. Both have good safety profiles in clinical use.

Comments

Sign in to join the discussion

تحذير: هذا الكود مقدم من قبل المجتمع ويهدف لغرض البحث فقط. لا يتحقق Peptide Contacts من سلامة أو فعالية الأكواد المقدمة. استشر محترف صحي مؤهل قبل استخدام أي بروتوكول بروتيني.